Abstract
Toll-like receptors (TLRs), which are mainly expressed in antigen presenting cells, perform a critical role in innate immunity by recognizing the specific structural patterns of pathogens and transducing signals to induce an inflammatory reaction. Although it has been reported that various solid cancers express endosomal TLRs, TLR3, 7, 8, and 9, the cellular and molecular function of TLRs in tumorigenesis has not yet been elucidated. In this report, we identified the expression of TLR3 and TLR7 in the human breast cancer cell line MCF-7 and found that TLRs stimulated with their specific ligand induced an anti-tumoral effect in this cell line. Among four synthetic commercial agonists of TLR3 and 7, Poly(I:C) and imiquimod (IMQ) proved to have superior anti-tumoral activity over the other agonists. A decreased growth rate was observed in MCF-7 cells treated with either TLR agonist. The decreased growth rate was due to autophagy and autophagy-induced cell death because treatment with 3-methyladenine, inhibitor of autophagy rescued the growth rate and increased the expression levels of autophagy-related genes. Moreover, survival of MCF-7 cells significantly decreased when the cells were stimulated simultaneously with TLR agonists and radiation exposure. Therefore, this study can be applied to developing a therapeutic adjuvant of TLR agonists in radiotherapy for radio-resistant breast cancer treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Akira S (2006) TLR signaling. Curr. Top. Microbiol.Immunol. 311: 1–16.
Celis E (2007) Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res. 67: 7945–7947.
Choi SS, Chung E and Jung YJ (2010) Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity. J. Microbiol. 48: 512–517.
Cormary C, Hiver E, Mariame B, Favre G and Tilkin-Mariame AF (2005) Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cancer Gene Ther. 12: 963–972.
Djavaheri-Mergny M, Maiuri MC and Kroemer G (2010) Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 29: 1717–1719.
Dotti G (2009) Blocking PD-1 in cancer immunotherapy. Blood 114: 1457–1458.
Egen JG, Kuhns MS and Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611–618.
Elpek KG, Lacelle C, Singh NP, Yolcu ES and Shirwan H (2007) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178: 6840–6848.
Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10: 554–567.
Gyrd-Hansen M and Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10: 561–574.
Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, Inagaki F and Ohsumi Y (2007) The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 282: 37298–37302.
Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218–224.
Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 19: 5720–5728.
Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184–1194.
Kumar B, Joshi J, Kumar A, Pandey BN, Hazra B and Mishra KP (2007) Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol. Cell. Biochem. 304: 287–296.
Mathew R, Karantza-Wadsworth V and White E (2007) Role of autophagy in cancer. Nat. Rev. Cancer 7: 961–967.
Medzhitov R and Janeway C, Jr. (2000a) Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173: 89–97.
Medzhitov R and Janeway C, Jr. (2000b) The Toll receptor family and microbial recognition. Trends Microbiol. 8: 452–456.
Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F and Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188: 177–182.
Mizushima N and Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542–545.
Mougel L, Tarpin M, Albert P, Le Naour R, Devy J, Kaplan H, Venteo L, Carlier A and Madoulet C (2004) Three-dimensional culture and multidrug resistance: effects on immune reactivity of MCF-7 cells by monocytes. Anticancer Res. 24: 935–941.
Peng JC, Hyde C, Pai S, O’sullivan BJ, Nielsen LK and Thomas R (2006) Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions. J. Immunother. 29: 606–615.
Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322–3330.
Roses RE, Xu M, Koski GK and Czerniecki BJ (2008) Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27: 200–207.
Schwartz MJ, Liu H, Hwang DH, Kawamoto H and Scherr DS (2009) Antitumor effects of an imidazoquinoline in renal cell carcinoma. Urology 73: 1156–1162.
Smits EL, Ponsaerts P, Berneman ZN and Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859–875.
Suzuki N, Suzuki S and Yeh WC (2002) IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23: 503–506.
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66: 1147–1154.
Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megias D, Mulero F et al. (2009) Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16: 103–114.
Tse K and Horner AA (2007) Update on toll-like receptor-directed therapies for human disease. Ann. Rheum. Dis. 66Suppl 3: iii77–80.
Vidal D, Matias-Guiu X and Alomar A (2004) Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br. J. Dermatol. 151: 656–662.
Wang R, Wang X, Li B, Lin F, Dong K, Gao P and Zhang HZ (2009) Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 117: 45–54.
Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ (2005) The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 65: 10338–10346.
Watts C, West MA and Zaru R (2010) TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 22: 124–130.
Xie Z and Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 9: 1102–1109.
Yi JY, Jung YJ, Choi SS, Hwang J and Chung E (2009) Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells. Biochem. Biophys. Res. Commun. 386: 455–458.
Zois CE and Koukourakis MI (2009) Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies?. Autophagy 5: 442–450.
Author information
Authors and Affiliations
Corresponding author
Additional information
The first two authors, SJK and JHT, contributed equally.
Rights and permissions
About this article
Cite this article
Kang, SJ., Tak, JH., Cho, JH. et al. Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer. Genes Genom 32, 599–606 (2010). https://doi.org/10.1007/s13258-010-0139-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13258-010-0139-x